PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

Abstract Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.
PMID
Related Publications

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.

Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials.

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title journal of clinical oncology : official journal of the american society of clinical oncology
Publication Year Start
%A Seng, Sonia; Liu, Ziyue; Chiu, Sophia K.; Proverbs-Singh, Tracy; Sonpavde, Guru; Choueiri, Toni K.; Tsao, Che-Kai; Yu, Menggang; Hahn, Noah M.; Oh, William K.; Galsky, Matthew D.
%T Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
%J Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 30, no. 35, pp. 4416-4426
%D 12/2012
%V 30
%N 35
%M eng
%B Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.
%K Aged, Cisplatin, Humans, Incidence, Middle Aged, Neoplasms, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Venous Thromboembolism
%P 4416
%L 4426
%Y 10.1200/JCO.2012.42.4358
%W PHY
%G AUTHOR
%R 2012.......30.4416S

@Article{Seng2012,
author="Seng, Sonia
and Liu, Ziyue
and Chiu, Sophia K.
and Proverbs-Singh, Tracy
and Sonpavde, Guru
and Choueiri, Toni K.
and Tsao, Che-Kai
and Yu, Menggang
and Hahn, Noah M.
and Oh, William K.
and Galsky, Matthew D.",
title="Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.",
journal="Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
year="2012",
month="Dec",
day="10",
volume="30",
number="35",
pages="4416--4426",
keywords="Aged",
keywords="Cisplatin",
keywords="Humans",
keywords="Incidence",
keywords="Middle Aged",
keywords="Neoplasms",
keywords="Randomized Controlled Trials as Topic",
keywords="Retrospective Studies",
keywords="Risk Factors",
keywords="Venous Thromboembolism",
abstract="Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.",
issn="1527-7755",
doi="10.1200/JCO.2012.42.4358",
url="http://www.ncbi.nlm.nih.gov/pubmed/23150697",
language="eng"
}

%0 Journal Article
%T Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
%A Seng, Sonia
%A Liu, Ziyue
%A Chiu, Sophia K.
%A Proverbs-Singh, Tracy
%A Sonpavde, Guru
%A Choueiri, Toni K.
%A Tsao, Che-Kai
%A Yu, Menggang
%A Hahn, Noah M.
%A Oh, William K.
%A Galsky, Matthew D.
%J Journal of clinical oncology : official journal of the American Society of Clinical Oncology
%D 2012
%8 Dec 10
%V 30
%N 35
%@ 1527-7755
%G eng
%F Seng2012
%X Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.
%K Aged
%K Cisplatin
%K Humans
%K Incidence
%K Middle Aged
%K Neoplasms
%K Randomized Controlled Trials as Topic
%K Retrospective Studies
%K Risk Factors
%K Venous Thromboembolism
%U http://dx.doi.org/10.1200/JCO.2012.42.4358
%U http://www.ncbi.nlm.nih.gov/pubmed/23150697
%P 4416-4426

PT Journal
AU Seng, S
   Liu, Z
   Chiu, SK
   Proverbs-Singh, T
   Sonpavde, G
   Choueiri, TK
   Tsao, C
   Yu, M
   Hahn, NM
   Oh, WK
   Galsky, MD
TI Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
SO Journal of clinical oncology : official journal of the American Society of Clinical Oncology
JI J. Clin. Oncol.
PD Dec
PY 2012
BP 4416
EP 4426
VL 30
IS 35
DI 10.1200/JCO.2012.42.4358
LA eng
DE Aged; Cisplatin; Humans; Incidence; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Venous Thromboembolism
AB Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.
ER

PMID- 23150697
OWN - NLM
STAT- MEDLINE
DA  - 20121211
DCOM- 20130506
LR  - 20131121
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 30
IP  - 35
DP  - 2012 Dec 10
TI  - Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a 
      systematic review and meta-analysis.
PG  - 4416-26
LID - 10.1200/JCO.2012.42.4358 [doi]
AB  - PURPOSE: Several reports suggest that cisplatin is associated with an increased
      risk of thromboembolism. However, because the excess risk of venous
      thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well 
      described, we conducted a systemic review and meta-analysis of randomized
      controlled trials evaluating the incidence and risk of VTEs associated with
      cisplatin-based chemotherapy. METHODS: PubMed was searched for articles published
      from January 1, 1990, to December 31, 2010. Eligible studies included prospective
      randomized phase II and III trials evaluating cisplatin-based versus
      non-cisplatin-based chemotherapy in patients with solid tumors. Data on all-grade
      VTEs were extracted. Study quality was calculated using Jadad scores. Incidence
      rates, relative risks (RRs), and 95% CIs were calculated using a random effects
      model. RESULTS: A total of 8,216 patients with various advanced solid tumors from
      38 randomized controlled trials were included. The incidence of VTEs was 1.92%
      (95% CI, 1.07 to 2.76) in patients treated with cisplatin-based chemotherapy and 
      0.79% (95% CI, 0.45 to 1.13) in patients treated with non-cisplatin-based
      regimens. Patients receiving cisplatin-based chemotherapy had a significantly
      increased risk of VTEs (RR, 1.67; 95% CI, 1.25 to 2.23; P = .01). Exploratory
      subgroup analysis revealed the highest RR of VTEs in patients receiving a weekly 
      equivalent cisplatin dose > 30 mg/m(2) (2.71; 95% CI, 1.17 to 6.30; P = .02) and 
      in trials reported during 2000 to 2010 (1.72; 95% CI, 1.27 to 2.34; P = .01).
      CONCLUSION: Cisplatin is associated with a significant increase in the risk of
      VTEs in patients with advanced solid tumors when compared with
      non-cisplatin-based chemotherapy.
FAU - Seng, Sonia
AU  - Seng S
AD  - Southcoast Centers for Cancer Care, Fairhaven, MA, USA.
FAU - Liu, Ziyue
AU  - Liu Z
FAU - Chiu, Sophia K
AU  - Chiu SK
FAU - Proverbs-Singh, Tracy
AU  - Proverbs-Singh T
FAU - Sonpavde, Guru
AU  - Sonpavde G
FAU - Choueiri, Toni K
AU  - Choueiri TK
FAU - Tsao, Che-Kai
AU  - Tsao CK
FAU - Yu, Menggang
AU  - Yu M
FAU - Hahn, Noah M
AU  - Hahn NM
FAU - Oh, William K
AU  - Oh WK
FAU - Galsky, Matthew D
AU  - Galsky MD
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121113
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
CIN - Strahlenther Onkol. 2013 Aug;189(8):704-5. PMID: 23793866
MH  - Aged
MH  - Cisplatin/administration & dosage/*adverse effects/therapeutic use
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Neoplasms/*blood/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Venous Thromboembolism/*chemically induced
EDAT- 2012/11/15 06:00
MHDA- 2013/05/07 06:00
CRDT- 2012/11/15 06:00
PHST- 2012/11/13 [aheadofprint]
AID - JCO.2012.42.4358 [pii]
AID - 10.1200/JCO.2012.42.4358 [doi]
PST - ppublish
SO  - J Clin Oncol. 2012 Dec 10;30(35):4416-26. doi: 10.1200/JCO.2012.42.4358. Epub
      2012 Nov 13.
TY  - JOUR
AU  - Seng, Sonia
AU  - Liu, Ziyue
AU  - Chiu, Sophia K.
AU  - Proverbs-Singh, Tracy
AU  - Sonpavde, Guru
AU  - Choueiri, Toni K.
AU  - Tsao, Che-Kai
AU  - Yu, Menggang
AU  - Hahn, Noah M.
AU  - Oh, William K.
AU  - Galsky, Matthew D.
PY  - 2012/Dec/10
TI  - Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
T2  - J. Clin. Oncol.
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
SP  - 4416
EP  - 4426
VL  - 30
IS  - 35
KW  - Aged
KW  - Cisplatin
KW  - Humans
KW  - Incidence
KW  - Middle Aged
KW  - Neoplasms
KW  - Randomized Controlled Trials as Topic
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Venous Thromboembolism
N2  - Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.
SN  - 1527-7755
UR  - http://dx.doi.org/10.1200/JCO.2012.42.4358
UR  - http://www.ncbi.nlm.nih.gov/pubmed/23150697
ID  - Seng2012
ER  - 
<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
<b:Source>
<b:Tag>Seng2012</b:Tag>
<b:SourceType>ArticleInAPeriodical</b:SourceType>
<b:Year>2012</b:Year>
<b:Month>Dec</b:Month>
<b:Day>10</b:Day>
<b:PeriodicalName>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</b:PeriodicalName>
<b:Volume>30</b:Volume>
<b:Issue>35</b:Issue>
<b:Pages>4416-4426</b:Pages>
<b:Author>
<b:Author><b:NameList>
<b:Person><b:Last>Seng</b:Last><b:First>Sonia</b:First></b:Person>
<b:Person><b:Last>Liu</b:Last><b:First>Ziyue</b:First></b:Person>
<b:Person><b:Last>Chiu</b:Last><b:First>Sophia</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Proverbs-Singh</b:Last><b:First>Tracy</b:First></b:Person>
<b:Person><b:Last>Sonpavde</b:Last><b:First>Guru</b:First></b:Person>
<b:Person><b:Last>Choueiri</b:Last><b:First>Toni</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Tsao</b:Last><b:First>Che-Kai</b:First></b:Person>
<b:Person><b:Last>Yu</b:Last><b:First>Menggang</b:First></b:Person>
<b:Person><b:Last>Hahn</b:Last><b:First>Noah</b:First><b:Middle>M</b:Middle></b:Person>
<b:Person><b:Last>Oh</b:Last><b:First>William</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Galsky</b:Last><b:First>Matthew</b:First><b:Middle>D</b:Middle></b:Person>
</b:NameList></b:Author>
</b:Author>
<b:Title>Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.</b:Title>
 <b:ShortTitle>J. Clin. Oncol.</b:ShortTitle>
<b:Comments>Several reports suggest that cisplatin is associated with an increased risk of thromboembolism. However, because the excess risk of venous thromboembolic events (VTEs) with cisplatin-based chemotherapy has not been well described, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of VTEs associated with cisplatin-based chemotherapy.</b:Comments>
</b:Source>
</b:Sources>